Citi Reiterates Buy Rating on Caribou Biosciences Inc. (CRBU)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/29/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- BioNTech ends colorectal cancer mRNA therapy trial early
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Needham sees mature node semiconductor strength in latest tracker
Evercore ISI Downgrades Caribou Biosciences Inc. (CRBU) to In Line
June 3, 2024 6:25 AM EDTEvercore ISI analyst Liisa Bayko downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Outperform to In Line with a price target of $3.00 (from $13.00).
The analyst comments "CRBU may have unlocked the key to allogenic CAR-T. But we are not yet convinced that it will be... More
